

Kirstine N Bojsen-Müller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8120566/publications.pdf>

Version: 2024-02-01

51
papers

2,511
citations

279798

23
h-index

197818

49
g-index

52
all docs

52
docs citations

52
times ranked

3405
citing authors

#	ARTICLE	IF	CITATIONS
1	GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment. <i>Pharmacological Research</i> , 2022, 176, 106058.	7.1	13
2	Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux-en-Y gastric bypass. <i>Physiological Reports</i> , 2022, 10, e15157.	1.7	3
3	On measurements of glucagon secretion in healthy, obese, and Roux-en-Y gastric bypass operated individuals using sandwich ELISA. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2022, 82, 75-83.	1.2	7
4	Early effects of Roux-en-Y gastric bypass on dietary fatty acid absorption and metabolism in people with obesity and normal glucose tolerance. <i>International Journal of Obesity</i> , 2022, 46, 1359-1365.	3.4	0
5	Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy. <i>Frontiers in Nutrition</i> , 2022, 9, 889710.	3.7	4
6	Effects of Roux-en-Y gastric bypass on circulating follistatin, activin A, and peripheral ActRIIB signaling in humans with obesity and type 2 diabetes. <i>International Journal of Obesity</i> , 2021, 45, 316-325.	3.4	3
7	The Role of Hepatic Fat Accumulation in Glucose and Insulin Homeostasis Dysregulation by the Liver. <i>Journal of Clinical Medicine</i> , 2021, 10, 390.	2.4	8
8	Follistatin secretion is enhanced by protein, but not glucose or fat ingestion, in obese persons independently of previous gastric bypass surgery. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G753-G758.	3.4	1
9	Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass. <i>Frontiers in Endocrinology</i> , 2021, 12, 681116.	3.5	7
10	Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. <i>New England Journal of Medicine</i> , 2021, 384, 1719-1730.	27.0	171
11	The role of GLP-1 in postprandial glucose metabolism after bariatric surgery: a narrative review of human GLP-1 receptor antagonist studies. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 1383-1391.	1.2	19
12	Neurotensin secretion after Roux-en-Y gastric bypass, sleeve gastrectomy, and truncal vagotomy with pyloroplasty. <i>Neurogastroenterology and Motility</i> , 2021, , e14210.	3.0	2
13	Plasma GDF15 levels are similar between subjects after bariatric surgery and matched controls and are unaffected by meals. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021, 321, E443-E452.	3.5	5
14	Metabolic improvement after gastric bypass correlates with changes in IGF-regulatory proteins stanniocalcin-2 and IGFBP-4. <i>Metabolism: Clinical and Experimental</i> , 2021, 124, 154886.	3.4	8
15	Intestinal sensing and handling of dietary lipids in gastric bypass-operated patients and matched controls. <i>American Journal of Clinical Nutrition</i> , 2020, 111, 28-41.	4.7	7
16	Mechanisms Underlying Absent Training-Induced Improvement in Insulin Action in Lean, Hyperandrogenic Women With Polycystic Ovary Syndrome. <i>Diabetes</i> , 2020, 69, 2267-2280.	0.6	13
17	Bilio-enteric flow and plasma concentrations of bile acids after gastric bypass and sleeve gastrectomy. <i>International Journal of Obesity</i> , 2020, 44, 1872-1883.	3.4	13
18	No effects of a 6-week intervention with a glucagon-like peptide-1 receptor agonist on pancreatic volume and oedema in obese men without diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1837-1846.	4.4	4

#	ARTICLE	IF	CITATIONS
19	The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 318, E956-E964.	3.5	13
20	Secretin release after Roux-en-Y gastric bypass reveals a population of glucose-sensitive S cells in distal small intestine. <i>International Journal of Obesity</i> , 2020, 44, 1859-1871.	3.4	25
21	Responses of gut and pancreatic hormones, bile acids, and fibroblast growth factor-21 differ to glucose, protein, and fat ingestion after gastric bypass surgery. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G661-G672.	3.4	27
22	Mechanisms involved in follistatin-induced hypertrophy and increased insulin action in skeletal muscle. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 1241-1257.	7.3	47
23	Sustained Improvements in Glucose Metabolism Late After Roux-En-Y Gastric Bypass Surgery in Patients with and Without Preoperative Diabetes. <i>Scientific Reports</i> , 2019, 9, 15154.	3.3	6
24	Pros and cons of Roux en-Y gastric bypass surgery in obese patients with type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2019, 14, 243-257.	2.4	5
25	Postprandial Nutrient Handling and Gastrointestinal Hormone Secretion After Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy. <i>Gastroenterology</i> , 2019, 156, 1627-1641.e1.	1.3	99
26	Effect of bariatric surgery on plasma GDF15 in humans. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2019, 316, E615-E621.	3.5	25
27	Mechanisms of action of a carbohydrate-reduced, high-protein diet in reducing the risk of postprandial hypoglycemia after Roux-en-Y gastric bypass surgery. <i>American Journal of Clinical Nutrition</i> , 2019, 110, 296-304.	4.7	22
28	Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss. <i>Surgery for Obesity and Related Diseases</i> , 2018, 14, 708-714.	1.2	144
29	Systems Signatures Reveal Unique Remission-path of Type 2 Diabetes Following Roux-en-Y Gastric Bypass Surgery. <i>EBioMedicine</i> , 2018, 28, 234-240.	6.1	5
30	Plasma Proteome Profiling Reveals Dynamics of Inflammatory and Lipid Homeostasis Markers after Roux-En-Y Gastric Bypass Surgery. <i>Cell Systems</i> , 2018, 7, 601-612.e3.	6.2	80
31	Hepatic Insulin Clearance in Regulation of Systemic Insulin Concentrations—Role of Carbohydrate and Energy Availability. <i>Diabetes</i> , 2018, 67, 2129-2136.	0.6	74
32	Variable reliability of surrogate measures of insulin sensitivity after Roux-en-Y gastric bypass. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2017, 312, R797-R805.	1.8	15
33	Chenodeoxycholic acid stimulates glucagon-like peptide-1 secretion in patients after Roux-en-Y gastric bypass. <i>Physiological Reports</i> , 2017, 5, e13140.	1.7	32
34	Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production. <i>Cell Reports</i> , 2017, 21, 1452-1460.	6.4	28
35	Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota. <i>Genome Medicine</i> , 2016, 8, 67.	8.2	260
36	Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2016, 310, E505-E514.	3.5	56

#	ARTICLE	IF	CITATIONS
37	No Islet Cell Hyperfunction, but Altered Gut-Islet Regulation and Postprandial Hypoglycemia in Glucose-Tolerant Patients 3 Years After Gastric Bypass Surgery. <i>Obesity Surgery</i> , 2016, 26, 2263-2267.	2.1	20
38	In vivo and in vitro degradation of peptide YY ₃₆ to inactive peptide YY ₃₄ in humans. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2016, 310, R866-R874.	1.8	46
39	Enhanced insulin signaling in human skeletal muscle and adipose tissue following gastric bypass surgery. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2015, 309, R510-R524.	1.8	42
40	Immediate enhancement of first-phase insulin secretion and unchanged glucose effectiveness in patients with type 2 diabetes after Roux-en-Y gastric bypass. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 308, E535-E544.	3.5	62
41	Improvements in Glucose Metabolism Early After Gastric Bypass Surgery Are Not Explained by Increases in Total Bile Acids and Fibroblast Growth Factor 19 Concentrations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E396-E406.	3.6	89
42	Updates in weight loss surgery and gastrointestinal peptides. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2015, 22, 21-28.	2.3	24
43	Accelerated protein digestion and amino acid absorption after Roux-en-Y gastric bypass. <i>American Journal of Clinical Nutrition</i> , 2015, 102, 600-607.	4.7	50
44	Mechanisms of improved glycaemic control after Roux-en-Y gastric bypass. <i>Danish Medical Journal</i> , 2015, 62, B5057.	0.5	12
45	Early Enhancements of Hepatic and Later of Peripheral Insulin Sensitivity Combined With Increased Postprandial Insulin Secretion Contribute to Improved Glycemic Control After Roux-en-Y Gastric Bypass. <i>Diabetes</i> , 2014, 63, 1725-1737.	0.6	220
46	Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?. <i>Diabetologia</i> , 2014, 57, 1919-1926.	6.3	156
47	Effects of gastric bypass surgery on glucose absorption and metabolism during a mixed meal in glucose-tolerant individuals. <i>Diabetologia</i> , 2013, 56, 2250-2254.	6.3	100
48	Exaggerated release and preserved insulinotropic action of glucagon-like peptide-1 underlie insulin hypersecretion in glucose-tolerant individuals after Roux-en-Y gastric bypass. <i>Diabetologia</i> , 2013, 56, 2679-2687.	6.3	82
49	Reduction in cardiovascular risk factors and insulin dose, but no beta-cell regeneration 1 year after Roux-en-Y gastric bypass in an obese patient with type 1 diabetes: A case report. <i>Obesity Research and Clinical Practice</i> , 2013, 7, e269-e274.	1.8	18
50	Increased Hepatic Insulin Clearance After Roux-en-Y Gastric Bypass. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E1066-E1071.	3.6	66
51	Exaggerated Glucagon-Like Peptide 1 Response Is Important for Improved β^2 -Cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2013, 62, 3044-3052.	0.6	262